REG - Smith & Nephew Plc - Directorate Change

Smith & NephewAnnouncement

20/06/2022 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220620:nRST1955Pa&default-theme=true

RNS Number : 1955P  Smith & Nephew Plc  20 June 2022

20 June 2022

 

 

Smith+Nephew announces new Senior Independent Director

 

 

 

Smith & Nephew plc (LSE:SN, NYSE:SNN) announces that Robin Freestone has
decided to step down as Senior Independent Director and as a Non-Executive
Director of Smith & Nephew plc with effect from 30 September 2022. Marc
Owen, Non-Executive Director, will be appointed as Senior Independent Director
with effect from the same date.

 

Mr Freestone was appointed as a Non-Executive Director in September 2015 and
subsequently appointed as Senior Independent Director in April 2019. Mr Owen
was appointed as a Non-Executive Director in October 2017. In addition to his
appointment as Senior Independent Director, Mr Owen will continue in his role
as Chair of the Compliance & Culture Committee and as a member of the
Audit Committee and Nomination & Governance Committee. He will take over
from Mr Freestone in leading the search for a new Chair of the company.

 

The Board would like to thank Mr Freestone for his commitment and contribution
to the Board and the Company and to congratulate Mr Owen on his new
appointment.

 

 

Enquiries

 Investors
 Andrew Swift                      +44 (0) 1923 477433
 Smith+Nephew
 Media
 Charles Reynolds                  +44 (0) 1923 477314
 Smith+Nephew

 Susan Gilchrist / Ayesha Bharmal  +44 (0) 20 7404 5959
 Brunswick

 

 

 

About Smith+Nephew

Smith+Nephew is a portfolio medical technology business focused on the repair,
regeneration and replacement of soft and hard tissue. We exist to restore
people's bodies and their self-belief by using technology to take the limits
off living. We call this purpose 'Life Unlimited'. Our 18,000 employees
deliver this mission every day, making a difference to patients' lives
through the excellence of our product portfolio, and the invention and
application of new technologies across our three global franchises of
Orthopaedics, Sports Medicine & ENT and Advanced Wound Management.

Founded in Hull, UK, in 1856, we now operate in more than 100 countries, and
generated annual sales of $5.2 billion in 2021. Smith+Nephew is a constituent
of the FTSE100 (LSE:SN, NYSE:SNN). The terms 'Group' and 'Smith+Nephew' are
used to refer to Smith & Nephew plc and its consolidated subsidiaries,
unless the context requires otherwise.

For more information about Smith+Nephew, please visit www.smith-nephew.com
(http://www.smith-nephew.com/) and follow us on Twitter
(http://www.twitter.com/smithnephewplc) , LinkedIn
(http://www.linkedin.com/company/smith-%26-nephew) , Instagram
(https://www.instagram.com/smithnephewmeded/) or Facebook
(http://www.facebook.com/smithnephewplc) .

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  BOABSGDLSXBDGDL